ebook: Vaccines in the digital age
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
List view / Grid view
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
LifeArc and the Medical Research Council have funded a new drug screening facility that will be established to accelerate COVID-19 drug discovery.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Computational drug screening has shown that chemotherapy drug pralatrexate could potentially be repurposed to treat COVID-19.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Scientists have created a drug discovery platform that enables the discovery and optimisation of RNA-targeting compounds.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
A new study shows that methacycline, a commonly used antibiotic, can reduce the neurological damage caused by Zika virus infections in mice.
Researchers have found a compound that can prevent up-regulation of CD14, a key inflammatory protein, in cells.